Can­del's vi­ral ther­a­py shows promis­ing sur­vival in small pan­cre­at­ic can­cer study

To Can­del Ther­a­peu­tics CEO Paul Pe­ter Tak, the biotech’s vi­ral im­munother­a­py has passed the “bloody ob­vi­ous test” in pan­cre­at­ic can­cer, and it’s prepar­ing to start …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER